1,340 reports of this reaction
2.4% of all AMITRIPTYLINE HYDROCHLORIDE reports
#5 most reported adverse reaction
DYSPNOEA is the #5 most commonly reported adverse reaction for AMITRIPTYLINE HYDROCHLORIDE, manufactured by Advagen Pharma Ltd. There are 1,340 FDA adverse event reports linking AMITRIPTYLINE HYDROCHLORIDE to DYSPNOEA. This represents approximately 2.4% of all 56,602 adverse event reports for this drug.
Patients taking AMITRIPTYLINE HYDROCHLORIDE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for AMITRIPTYLINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for AMITRIPTYLINE HYDROCHLORIDE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 1,340 FDA reports for AMITRIPTYLINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.4% of all adverse event reports for AMITRIPTYLINE HYDROCHLORIDE, making it a notable side effect.
If you experience dyspnoea while taking AMITRIPTYLINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.